JP2020503891A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020503891A5 JP2020503891A5 JP2019551736A JP2019551736A JP2020503891A5 JP 2020503891 A5 JP2020503891 A5 JP 2020503891A5 JP 2019551736 A JP2019551736 A JP 2019551736A JP 2019551736 A JP2019551736 A JP 2019551736A JP 2020503891 A5 JP2020503891 A5 JP 2020503891A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- cells
- cell
- car
- cell according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000004027 cell Anatomy 0.000 claims 16
- 102100031585 ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Human genes 0.000 claims 15
- 101000777636 Homo sapiens ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Proteins 0.000 claims 15
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims 11
- 210000000822 natural killer cell Anatomy 0.000 claims 7
- 206010028980 Neoplasm Diseases 0.000 claims 4
- 201000011510 cancer Diseases 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 2
- 102000009058 Death Domain Receptors Human genes 0.000 claims 1
- 108010049207 Death Domain Receptors Proteins 0.000 claims 1
- 208000034578 Multiple myelomas Diseases 0.000 claims 1
- 102000003800 Selectins Human genes 0.000 claims 1
- 108090000184 Selectins Proteins 0.000 claims 1
- 230000030833 cell death Effects 0.000 claims 1
- 201000005787 hematologic cancer Diseases 0.000 claims 1
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 claims 1
- 239000003446 ligand Substances 0.000 claims 1
- 230000003211 malignant effect Effects 0.000 claims 1
- 201000000050 myeloid neoplasm Diseases 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023017202A JP2023052980A (ja) | 2016-12-09 | 2023-02-07 | 操作されたナチュラルキラー細胞およびその使用 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662432302P | 2016-12-09 | 2016-12-09 | |
| US62/432,302 | 2016-12-09 | ||
| PCT/EP2017/082292 WO2018104562A1 (en) | 2016-12-09 | 2017-12-11 | Engineered natural killer cells and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023017202A Division JP2023052980A (ja) | 2016-12-09 | 2023-02-07 | 操作されたナチュラルキラー細胞およびその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020503891A JP2020503891A (ja) | 2020-02-06 |
| JP2020503891A5 true JP2020503891A5 (OSRAM) | 2021-01-21 |
| JP7228900B2 JP7228900B2 (ja) | 2023-02-27 |
Family
ID=60937693
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019551736A Active JP7228900B2 (ja) | 2016-12-09 | 2017-12-11 | 操作されたナチュラルキラー細胞およびその使用 |
| JP2023017202A Pending JP2023052980A (ja) | 2016-12-09 | 2023-02-07 | 操作されたナチュラルキラー細胞およびその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023017202A Pending JP2023052980A (ja) | 2016-12-09 | 2023-02-07 | 操作されたナチュラルキラー細胞およびその使用 |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US10799536B2 (OSRAM) |
| EP (4) | EP3454871B1 (OSRAM) |
| JP (2) | JP7228900B2 (OSRAM) |
| KR (1) | KR20190114966A (OSRAM) |
| CN (2) | CN117305250A (OSRAM) |
| AU (1) | AU2017371517B2 (OSRAM) |
| BR (1) | BR112019011450A2 (OSRAM) |
| CA (1) | CA3045386A1 (OSRAM) |
| DK (2) | DK3454871T3 (OSRAM) |
| ES (3) | ES2875005T3 (OSRAM) |
| MX (1) | MX2019006598A (OSRAM) |
| WO (1) | WO2018104562A1 (OSRAM) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10906951B2 (en) * | 2015-07-29 | 2021-02-02 | Onk Therapeutics Limited | Modified natural killer cells and natural killer cell lines having increased cytotoxicity |
| WO2017180587A2 (en) | 2016-04-11 | 2017-10-19 | Obsidian Therapeutics, Inc. | Regulated biocircuit systems |
| JP7373991B2 (ja) * | 2016-07-15 | 2023-11-06 | ビラクタ セラピューティクス，インク． | 免疫療法で使用するためのヒストン脱アセチル化酵素阻害剤 |
| KR20190114966A (ko) | 2016-12-09 | 2019-10-10 | 온키뮨 리미티드 | 조작된 자연 살해 세포 및 이의 용도 |
| WO2019222503A1 (en) * | 2018-05-16 | 2019-11-21 | Research Institute At Nationwide Children's Hospital | Generation of knock-out primary and expanded human nk cells using cas9 ribonucleoproteins |
| IL296050B2 (en) * | 2018-08-01 | 2024-12-01 | Immunitybio Inc | A quadricistronic system comprising a homing receptor or a cytokine, and chimeric antigen receptor for genetic modification of immunotherapies |
| WO2020047048A1 (en) * | 2018-08-29 | 2020-03-05 | Academia Sinica | Combination of natural killer cells with cyclophosphamide compounds for the treatment of cancer |
| US12331320B2 (en) | 2018-10-10 | 2025-06-17 | The Research Foundation For The State University Of New York | Genome edited cancer cell vaccines |
| KR102292657B1 (ko) | 2019-03-15 | 2021-08-24 | 한국과학기술연구원 | 암 상살 능력이 향상된 면역세포 |
| WO2020189942A1 (ko) * | 2019-03-15 | 2020-09-24 | 한국과학기술연구원 | 암 상살 능력이 향상된 면역세포 |
| CN109970869A (zh) * | 2019-04-12 | 2019-07-05 | 南京卡提医学科技有限公司 | 一种靶向人trail死亡受体的嵌合受体配体及其应用 |
| WO2020220027A1 (en) * | 2019-04-25 | 2020-10-29 | Purdue Research Foundation | Engineered natural killer cells redirected toward purinergic signaling, constructs thereof, and methods for using the same |
| CN114867485A (zh) * | 2019-10-31 | 2022-08-05 | 全国儿童医院研究所 | Cd38敲除的原代和扩增的人nk细胞的生成 |
| TW202146644A (zh) * | 2020-01-16 | 2021-12-16 | 育世博生物科技股份有限公司 | 一種新穎的ｃｄ１６陽性自然殺手細胞及一種培養ｃｄ１６陽性自然殺手細胞的方法 |
| US11230699B2 (en) | 2020-01-28 | 2022-01-25 | Immunitybio, Inc. | Chimeric antigen receptor-modified NK-92 cells targeting EGFR super-family receptors |
| WO2021209625A1 (en) * | 2020-04-17 | 2021-10-21 | Onk Therapeutics Limited | High potency natural killer cells |
| KR20220027785A (ko) * | 2020-08-27 | 2022-03-08 | 주식회사 셀리드 | 신규한 코로나바이러스 재조합 스파이크 단백질, 이를 코딩하는 폴리뉴클레오티드, 상기 폴리뉴클레오티드를 포함하는 벡터 및 상기 벡터를 포함하는 코로나바이러스감염증 예방 또는 치료용 백신 |
| WO2022047419A1 (en) | 2020-08-31 | 2022-03-03 | City Of Hope | Novel cell lines, methods of producing natural killer cells and uses thereof |
| CN114426583B (zh) * | 2020-10-29 | 2023-10-10 | 中国科学技术大学 | 用于急性髓系白血病的细胞疗法的嵌合抗原受体 |
| WO2022139517A1 (ko) | 2020-12-23 | 2022-06-30 | 주식회사 휴먼셀바이오 | 혈액 유래 물질 및 면역세포를 포함하는 암 또는 면역질환의 예방 또는 치료용 약학조성물 |
| WO2022263682A1 (en) | 2021-06-18 | 2022-12-22 | Onk Therapeutics Limited | Double knockout natural killer cells |
| EP4362957A1 (en) | 2021-07-01 | 2024-05-08 | Indapta Therapeutics, Inc. | Engineered natural killer (nk) cells and related methods |
| US20240327521A1 (en) * | 2021-07-29 | 2024-10-03 | Seattle Children's Hospital D/B/A Seattle Children's Research Institute | Synthetic nucleic acid elements for enhancing car t cell efficacy |
| EP4402155A2 (en) * | 2021-09-18 | 2024-07-24 | Sunnybay Biotech, Inc | Herv-k antibody, cell, vaccine, and drug therapeutics |
| CN118742560A (zh) * | 2021-12-03 | 2024-10-01 | 犹他大学研究基金会 | 高选择性cd229抗原结合结构域及使用方法 |
| CA3259982A1 (en) | 2022-06-30 | 2024-01-04 | Indapta Therapeutics Inc | COMBINATION OF MODIFIED NATURAL KILLER (NK) CELLS AND ANTIBODY THERAPY AND ASSOCIATED METHODS |
| EP4353741A1 (en) | 2022-10-14 | 2024-04-17 | ONK Therapeutics Limited | Double knockout natural killer cells |
| JP2025536042A (ja) | 2022-11-10 | 2025-10-30 | オーエヌケイ セラピューティクス リミテッド | 免疫調節薬を用いた併用療法 |
| WO2024238387A1 (en) * | 2023-05-12 | 2024-11-21 | Nkmax Co., Ltd. | Method of treating alzheimer's disease with expanded natural killer cells |
| WO2025059162A1 (en) | 2023-09-11 | 2025-03-20 | Dana-Farber Cancer Institute, Inc. | Car-engager containing il-2 variants to enhance the functionality of car t cells |
| WO2025073908A1 (en) | 2023-10-05 | 2025-04-10 | Onk Therapeutics Limited | Optimised il-15 constructs |
| WO2025146467A1 (en) | 2024-01-04 | 2025-07-10 | Onk Therapeutics Limited | Targeted il-15 construct delivery |
| KR20250118299A (ko) | 2024-01-29 | 2025-08-06 | 인하대학교 산학협력단 | 전기자극 시스템을 활용한 자연살해세포의 암세포 살상 능력 증진 방법 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060228710A1 (en) * | 2003-02-14 | 2006-10-12 | Morris David W | Novel therapeutic targets in cancer |
| EA015584B1 (ru) | 2005-03-23 | 2011-10-31 | Генмаб А/С | Антитело к cd38 человека и его применение |
| HRP20191115T1 (hr) | 2006-09-26 | 2019-09-20 | Genmab A/S | Anti-cd38 u kombinaciji s kortikosteroidima zajedno s jednim ne-kortikosteroidnim kemoterapeutikom za liječenje tumora |
| JP2010507366A (ja) | 2006-10-19 | 2010-03-11 | メルク アンド カンパニー インコーポレイテッド | インターロイキン−１３受容体α１の抗体アンタゴニスト |
| GB0724532D0 (en) | 2007-12-17 | 2008-01-30 | Nat Univ Ireland | Trail variants for treating cancer |
| EP2580243B1 (en) | 2010-06-09 | 2019-10-16 | Genmab A/S | Antibodies against human cd38 |
| EP2964753B1 (en) | 2013-03-07 | 2018-04-25 | Baylor College of Medicine | Targeting cd138 in cancer |
| JP6673838B2 (ja) * | 2014-02-14 | 2020-04-01 | セレクティスＣｅｌｌｅｃｔｉｓ | 免疫細胞と病的細胞の両方に存在する抗原を標的とするように操作された、免疫療法のための細胞 |
| CN106132423B (zh) * | 2014-02-14 | 2020-07-31 | 贝里坤制药股份有限公司 | 用诱导型嵌合多肽活化t细胞的方法 |
| WO2015142675A2 (en) | 2014-03-15 | 2015-09-24 | Novartis Ag | Treatment of cancer using chimeric antigen receptor |
| HRP20191400T1 (hr) | 2014-12-24 | 2019-11-15 | Aadigen Llc | Peptidi i nanočestice za unutarstaničnu isporuku molekula |
| CN107249604A (zh) | 2014-12-31 | 2017-10-13 | 人类起源公司 | 使用自然杀伤细胞治疗血液病症、实体瘤或感染性疾病的方法 |
| WO2016126608A1 (en) | 2015-02-02 | 2016-08-11 | Novartis Ag | Car-expressing cells against multiple tumor antigens and uses thereof |
| EP4286511A3 (en) | 2015-06-12 | 2024-03-06 | Lentigen Technology, Inc. | Method to treat cancer with engineered t-cells |
| US11655452B2 (en) | 2015-06-25 | 2023-05-23 | Icell Gene Therapeutics Inc. | Chimeric antigen receptors (CARs), compositions and methods of use thereof |
| EP3971284B1 (en) | 2015-07-29 | 2023-11-08 | ONK Therapeutics Limited | Modified natural killer cells and natural killer cell lines having increased cytotoxicity |
| CN105384825B (zh) | 2015-08-11 | 2018-06-01 | 南京传奇生物科技有限公司 | 一种基于单域抗体的双特异性嵌合抗原受体及其应用 |
| KR20190114966A (ko) * | 2016-12-09 | 2019-10-10 | 온키뮨 리미티드 | 조작된 자연 살해 세포 및 이의 용도 |
-
2017
- 2017-12-11 KR KR1020197019363A patent/KR20190114966A/ko not_active Ceased
- 2017-12-11 ES ES19176141T patent/ES2875005T3/es active Active
- 2017-12-11 BR BR112019011450A patent/BR112019011450A2/pt not_active IP Right Cessation
- 2017-12-11 US US15/837,576 patent/US10799536B2/en active Active
- 2017-12-11 CN CN202311063691.5A patent/CN117305250A/zh active Pending
- 2017-12-11 DK DK17825774.7T patent/DK3454871T3/da active
- 2017-12-11 AU AU2017371517A patent/AU2017371517B2/en active Active
- 2017-12-11 MX MX2019006598A patent/MX2019006598A/es unknown
- 2017-12-11 JP JP2019551736A patent/JP7228900B2/ja active Active
- 2017-12-11 EP EP17825774.7A patent/EP3454871B1/en active Active
- 2017-12-11 DK DK19176141.0T patent/DK3581190T3/da active
- 2017-12-11 WO PCT/EP2017/082292 patent/WO2018104562A1/en not_active Ceased
- 2017-12-11 ES ES21160170T patent/ES2926397T3/es active Active
- 2017-12-11 EP EP22179362.3A patent/EP4104841A1/en active Pending
- 2017-12-11 CN CN201780085686.0A patent/CN110248669B/zh active Active
- 2017-12-11 ES ES17825774T patent/ES2746856T3/es active Active
- 2017-12-11 EP EP19176141.0A patent/EP3581190B1/en active Active
- 2017-12-11 EP EP21160170.3A patent/EP3895712B1/en active Active
- 2017-12-11 CA CA3045386A patent/CA3045386A1/en active Pending
-
2020
- 2020-08-31 US US17/008,506 patent/US20210046118A1/en active Pending
-
2023
- 2023-02-07 JP JP2023017202A patent/JP2023052980A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020503891A5 (OSRAM) | ||
| HRP20161656T4 (hr) | Sredstva za vezanje na cd33 | |
| JP2016520074A5 (OSRAM) | ||
| PH12018501778A1 (en) | Antibodies to tigit | |
| EA202091590A1 (ru) | Антитела против pd-l1 и варианты их применения | |
| PH12019502356A1 (en) | Trem2 antigen binding proteins and uses thereof | |
| HRP20240719T1 (hr) | Kimerna i humanizirana monoklonska protutijela protiv ljudskog ctla4 i njihova upotreba | |
| JP2012254092A5 (OSRAM) | ||
| JP2014505463A5 (OSRAM) | ||
| JP2020526214A5 (OSRAM) | ||
| CL2018003608A1 (es) | Anticuerpo aislado o fragmento de unión a antígeno del mismo que se une específicamente interleucina-25 hjumana (il-2525); composición farmacéutica que lo comprende; uso de dicha composición farmacéutica para tratar una enfermedad o trastorno asociado con la actividad o expresión de il-25. (divisional solicitud 201700703) | |
| JP2017518258A5 (OSRAM) | ||
| JP2016502515A5 (OSRAM) | ||
| JP2015535691A5 (OSRAM) | ||
| NZ628528A (en) | Optimization of antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof | |
| WO2016014565A3 (en) | Treatment of cancer using humanized anti-bcma chimeric antigen receptor | |
| MX2022003249A (es) | Anticuerpos anti receptor del factor de necrosis tumoral 2 (tnfr2) y métodos de uso. | |
| JP2017513478A5 (OSRAM) | ||
| JP2014039548A5 (OSRAM) | ||
| JP2015131795A5 (OSRAM) | ||
| WO2015142675A3 (en) | Treatment of cancer using chimeric antigen receptor | |
| JP2018524326A5 (OSRAM) | ||
| MX2010010387A (es) | Anticuerpos especificos para el complejo de bcr y metodos para el uso de los mismos. | |
| HK1210792A1 (en) | Molecules with antigen binding and polyvalent fc gamma receptor binding activity | |
| JP2018509163A5 (OSRAM) |